Market Minds Advisory
Treatment-Resistant Depression Treatment Market

Treatment-Resistant Depression Treatment Market: Ketamine Therapy Reshapes Psychiatric Sourcing

Expanding insurance reimbursement for interventional psychiatry and rising esketamine adoption are pushing clinics toward rapid-acting therapies, pressuring pharmacotherapy augmentation regimens whose delayed onset increasingly conflicts with acute suicidality treatment protocols.

Lead Analyst

Alice Ballenger

Published

September 2026

Make Smarter Decisions with Customized Research Insights

Request a free sample report and evaluate market opportunities, growth trends, and competitive dynamics relevant to your business needs.

2025 MARKET VALUE$6.8BMarket Size 2025
2036 FORECAST VALUE$20.2BBase Case , 2026 to 2036
CAGR 2026 TO 203610.4 %Bull 11.8% / Bear 9.0%
INCREMENTAL OPPORTUNITY$12.7BNet 10- year value creation
EXPANSION MULTIPLE2.69x2036 value over 2026 base
Strategic Levers
M&A Pipeline
Regional Outlook
Country Rankings
Competitive Intelligence
Segmental Deep-dive
Call-Us : 91 93563 13602

Executive Snapshot and Market Trajectory

Johnson & Johnson and Neuronetics built the modern treatment-resistant depression category on pharmacotherapy augmentation regimens, and esketamine therapy is now the fastest growing answer to psychiatric clinics facing acute suicidality demand that oral augmentation cannot satisfy across most major healthcare systems worldwide each year today overall.
Johnson & Johnson and Neuronetics still command meaningful combined share of the category through years of clinical development investment and established psychiatric relationships, while expanding insurance reimbursement keeps growing the addressable treatment pool each year. Esketamine and TMS device formats have pulled treatment decisions firmly toward rapid-acting construction across acute care and outpatient psychiatric programmes, concentrated heavily in North America's dense regional interventional psychiatry base.
Five companies hold roughly a third of global category revenue, a moderately fragmented structure built on specialized clinical development that larger multinationals struggle to fully consolidate, and the order shifts more often than in mature pharmaceutical categories since clinics frequently re-tender treatment protocols across reimbursement policy cycles. Rising esketamine and TMS demand will determine how quickly rapid-acting therapies displace oral augmentation incumbents across every major healthcare channel each ongoing annual fiscal budget cycle overall.
Market Definition
This market covers therapeutic products and devices used to treat major depressive disorder that has not responded to at least two adequate antidepressant trials, including pharmacotherapy augmentation regimens, esketamine and ketamine-based therapies, transcranial magnetic stimulation devices, electroconvulsive therapy devices and services, and vagus nerve stimulation devices. It excludes standard first-line antidepressant monotherapy and general psychotherapy services not specifically indicated for treatment resistance.
Base Year Value
$6.8B in 2025 (MMA Primary Research Dataset, August 2026)
Forecast Period
2026 to 2036, eleven discrete annual values
CAGR
10.4% base case. Bull 11.8%. Bear 9.0%.
Fastest Growth Segment
Esketamine and Ketamine-Based Therapies: 16.8% CAGR
Fastest Growth Country
United States: 12.2% CAGR
Fastest Growth Region
South Asia and Pacific: 12.4% CAGR
Largest Region
North America: 32% of 2025 global value
Market Leaders
Johnson & Johnson (Janssen Pharmaceuticals), Neuronetics Inc, Magstim Company Ltd, LivaNova PLC, Otsuka Pharmaceutical Co Ltd. Source: MMA Analysis based on company annual reports.
Primary Survey
n=3,800 procurement and R&D decision-makers, Q4 2025, six countries
Methodology
Demand-side build-up, cross-validated against public data, 47 expert interviews

Treatment-Resistant Depression Treatment Market Forecast Scenarios

treatment-resistant-depression-treatment-market-size-forecast-scenario-1787299836683
Between 2020 and 2025, the market grew at a historical rate near 8.8 percent, reflecting steady adoption of established pharmacotherapy augmentation regimens and gradual esketamine uptake across acute care programmes, with TMS devices remaining a comparatively small share of total volume through most of this recovery period as conventional oral augmentation still dominated most clinical purchasing.
The base case assumes 10.4 percent annual growth through 2036, built on three mechanisms: expanding insurance reimbursement driving treatment purchasing volume, rising esketamine adoption supporting rapid-acting format growth, and East Asian psychiatric infrastructure expansion pulling forward volume well ahead of comparable Western adoption cycles still under gradual modernisation across most major producing regions, tracked closely by clinic procurement teams reviewing treatment cycles each year and every fiscal review cycle overall.
A bull case near 11.8 percent depends on national mental health parity enforcement holding firm across major markets still finalizing coverage policy for interventional psychiatry today. The bear case near 9.0 percent reflects continued payer budget caution around premium esketamine price differentials pushing some treatment toward augmentation alternatives in cost constrained healthcare markets worldwide each ongoing budget cycle overall.

Oral Augmentation Legacy Meets Rapid-Acting Demand

Treatment-resistant depression procurement has quietly become an onset speed and suicidality risk mitigation specification decision as much as a formulary sourcing one. The core function, achieving symptom remission after standard antidepressants fail, has not changed, but psychiatric clinics increasingly weigh onset speed alongside durability when planning new treatment protocols across every affected acute care and outpatient category worldwide. That shift already shapes new procurement evalua
TOP 5 CONCENTRATION34% CR5revenue share held by five largest global TRD treatment manufacturers
AVERAGE TREATMENT COURSE VALUE$8,200 per patienttypical full treatment course cost across major payer programmes
LEADING PRODUCING COUNTRYUSA, 29%share of global product value, by manufacturer home country
ESKETAMINE REVENUE SHARE26% of revenueshare of category revenue from esketamine and ketamine formats
OUTPATIENT CLINIC VOLUME SHARE58% of coursesshare of treatment courses delivered through outpatient psychiatric clinics
CLINICAL DEVELOPMENT COST SHARE43% of COGSinput cost weight from clinical trial and regulatory sourcing
Commercial behaviour splits by care setting and clinical criticality. Standard outpatient psychiatry still relies heavily on established oral augmentation regimens that have performed reliably for years, while acute care and specialty psychiatric centers increasingly specify esketamine and TMS device formats where onset speed carries meaningfully higher practical value than marginal cost savings. Distributors report this split sharpening recently across major healthcare systems.
The next decade turns on whether augmentation-focused manufacturers can build sufficient esketamine depth to compete for onset-driven clinical purchasing while defending their core outpatient relationships against rising specialty competitors. Manufacturers that solve both problems stand to capture share from an oral augmentation installed base that has dominated treatment-resistant depression for more than three decades of continuous psychiatric use worldwide. That transition will not happen overnight.
"Nobody switches a patient to esketamine because the mechanism sounds novel. They switch because the patient has been actively suicidal for six weeks and augmentation hasn't worked."
Director, Healthcare and Psychiatric Therapeutics Practice · MMA Healthcare Prac

Market Trends

Esketamine Adoption Accelerates Rapid-Acting Clinical Conversion

Esketamine adoption has expanded considerably as psychiatric clinics increasingly favor rapid-acting nasal spray formats that conventional oral augmentation struggles to support against advanced alternatives offering meaningfully faster symptom relief and reduced suicidality risk. Johnson & Johnson and Neuronetics have both reported expanded order books for esketamine and TMS therapy from major psychiatric networks in recent years, driven by clinical teams specifically seeking treatments that reduce hospitalization risk. Clinic data has documented meaningfully faster remission versus comparable augmentation-only programmes across audited comparisons reviewed by MMA analysts. Psychiatric networks across Europe and Asia have announced comparable expansions recently.
Market Impact: Reaches 27% of capacity investment

Mental Health Parity Policy Expands National Demand

National mental health parity policy adoption has expanded considerably as payers increasingly cover interventional psychiatry that legacy fee-limited coverage could not support at required treatment access levels. Magstim and LivaNova have both expanded dedicated interventional psychiatry portfolios targeting the more than 620 psychiatric networks adopting standardised treatment access protocols annually according to trade association data reviewed by MMA analysts. Programmes across Southeast Asia and Latin America have announced comparable adoption expansions over the past two years, reflecting the trend's broadening reach across multiple healthcare systems worldwide, tracked closely by procurement teams each cycle.
Market Impact: Adds 3,100-plus diagnosis-ready facilities

Market Opportunities and Growth Drivers

Expanding Psychiatric Clinic Network Capacity Drives Volume

Global psychiatric clinic network capacity continues expanding considerably across major healthcare systems, a shift that has fundamentally changed treatment demand patterns since new clinic construction commands meaningfully higher per-facility treatment volume than routine outpatient purchasing historically generated. Manufacturers have responded with dedicated facility-ready treatment bundles specifically engineered for these higher-volume requirements. An estimated 27 percent of new treatment-resistant depression purchasing now targets new clinic network construction, up considerably from a meaningfully smaller share just a decade earlier, reflecting accelerating healthcare investment across major markets worldwide, tracked closely by procurement teams.
Market Impact: Loses 5 to 8% share

Rising Diagnosed Prevalence Volume Expands Demand

Global diagnosed treatment-resistant depression prevalence has risen considerably in recent years, driven by rising demand for rapid-acting, evidence-based therapy offering higher remission outcomes and reduced hospitalization rates than conventional periodic-adjustment alternatives historically delivered. Manufacturers have responded by developing dedicated diagnosis-ready treatment lines specifically engineered for these tighter clinical requirements. New psychiatric procurement capacity is projected to grow considerably across major markets through the coming decade, each clinic requiring treatment capability capable of sustaining faster remission than conventional systems allow, across nearly every major healthcare network worldwide, reviewed closely by procurement analysts each year.
Market Impact: Limits adoption to 24% of clinics

Market Restraints and Challenges

High Esketamine Cost Slows Budget Constrained Adoption

Many payers in budget-constrained regions find the cost of esketamine therapy over conventional oral augmentation economically difficult, even where the remission case is well documented. The root cause is that annual healthcare budget cycles, not clinical outcome data, drive most coverage decisions, and lower-resource payers see meaningfully slower esketamine adoption than higher-resource payers facing the same coverage decision. Manufacturers have responded by developing tiered pricing programmes and simplified monitoring protocols specifically intended to narrow the cost gap across multiple budget-constrained healthcare markets worldwide, each year and every ongoing budget review cycle.
Market Impact: Lifts esketamine format share 26%

Fragmented Regulatory Monitoring Standards Slow Adoption

Esketamine and ketamine treatment compliance requires jurisdiction-specific monitored-administration data and testing infrastructure that many smaller clinics lack capacity to maintain, since multi-jurisdiction compliance differs meaningfully from single-market outpatient treatment most clinics already manage. This restricts advanced therapy adoption among smaller regional clinics serving fragmented, resource-constrained healthcare markets rather than large multinational psychiatric networks. Manufacturers have responded by developing simplified monitoring lookup tools and dedicated compliance support programmes specifically intended to lower the adoption barrier across multiple underserved regional markets worldwide, particularly among smaller clinics with limited compliance staff available today, reviewed each fiscal cycle by regional teams overall.
Market Impact: Covers 620-plus adopting psychiatric networks
3 additional market trends, 4 additional growth drivers, and 3 additional restraints and challenges are covered in the full report. Contact sales@marketmindsadvisory.com to access the complete intelligence.

Segment CAGR and Growth Architecture

Segmentation follows treatment modality, the classification psychiatric clinics, payers, and clinical formulary teams already use to distinguish augmentation, esketamine, TMS, and neurostimulation categories across every product type this report covers, spanning both established augmentation and rapidly emerging esketamine categories, from routine outpatient use through next-generation acute care formats now scaling worldwide each year across major markets.
treatment-resistant-depression-treatment-market-market-share-analysis-1787299837214

Esketamine and Ketamine-Based Therapies

Esketamine and ketamine-based therapies are the fastest-growing category as psychiatric clinics increasingly specify rapid-acting nasal spray and infusion formats to enable acute symptom relief across suicidality and treatment-resistant settings. The mechanism uses NMDA receptor modulation rather than monoamine reuptake inhibition, delivering meaningfully faster onset than conventional alternatives typically achieve. Johnson & Johnson and Neuronetics both compete directly in this segment, each pursuing expanded distribution relationships with psychiatric clinics worldwide. Growth concentrates among clinics serving high acute care demand, though broader adoption still depends on closing the remaining cost gap with established augmentation alternatives each year. Manufacturers investing early in this transition stand to capture disproportionate share as mental health parity mandates broaden across markets.
CAGR 16.8%

Transcranial Magnetic Stimulation Devices

Transcranial magnetic stimulation devices grow fastest among established categories as clinics increasingly specify non-invasive neurostimulation formats for applications requiring greater treatment tolerability than pharmacological methods provide. Magstim and LivaNova both hold significant positions in this segment, backed by years of neurostimulation engineering investment and established clinical relationships across major psychiatric systems worldwide. Growth concentrates among clinics specifically expanding outpatient neurostimulation programmes, though manufacturers face rising competitive pressure from esketamine alternatives in applications where onset speed weighs more heavily than tolerability on treatment decisions. Manufacturers with compact, lower-cost TMS designs increasingly win these smaller-scale deployments ahead of larger legacy competitors, particularly across regional clinics still building out dedicated neurostimulation referral relationships each year.
CAGR 13.2%
Full segment breakdown across 5 segments available in the complete report.

Regional Architecture and Country Demand Map

North America accounts for nearly a third of global treatment-resistant depression revenue, reflecting concentrated interventional psychiatry activity and dense reimbursement infrastructure, while South Asia and Pacific posts the fastest regional growth on expanding psychiatric capacity nationwide each year across the region's major purchasing markets and networks.

North America

The United States drives the majority of regional demand through its concentration of interventional psychiatry activity and its position as home base for Johnson & Johnson's and Neuronetics' commercial operations. Johnson & Johnson and Neuronetics both maintain domestic distribution and clinical training presence serving this demand directly. Rising esketamine adoption has meaningfully expanded demand for rapid-acting therapies across multiple regional healthcare networks in particular. Canada contributes a smaller but stable share, with psychiatric systems gradually expanding coverage for esketamine adoption following patterns already established in the United States. Mexico's demand ties increasingly to cross-border healthcare distribution networks serving both domestic and North American clinical programmes across every affected state and province today.
Share: 32% | CAGR: 11.6% (2026 to 2036)

Western Europe

Germany anchors regional demand through its well-established psychiatric care infrastructure and long-standing manufacturer distributor relationships built over decades of continuous clinical development. The United Kingdom follows closely, with National Health Service coverage commitments driving sustained treatment procurement across psychiatric networks nationwide. France and Switzerland contribute meaningful shares tied to established clinical research clusters supplying domestic and wider European treatment networks. Regional growth trails East Asia and South Asia because much of Western Europe's treatment-resistant depression base is already relatively mature, a pattern regional manufacturers expect to persist through continued gradual modernisation each fiscal year across most national markets and affiliated distribution channels monitored closely by regional procurement authorities each year overall.
Share: 24% | CAGR: 8.8% (2026 to 2036)
Regional intelligence for 5 additional markets available in the complete report: East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe. Contact sales@marketmindsadvisory.com.
treatment-resistant-depression-treatment-market-country-cagr-analysis-1787299837734

Where TRD Treatment Margin Concentrates

Margin follows onset speed depth and clinical relationship positioning, not unit volume alone. Manufacturers who win early psychiatric formulary relationships lock in multi-year purchasing streams that generic manufacturers struggle to match once the relationship is fully established across the clinic's entire treatment portfolio, a dynamic reshaping how manufacturers prioritise validation investment planning each budget year overall.

Winning Early Psychiatric Formulary Design Relationships

Manufacturers who secure treatment specification during a clinic's early formulary planning phase typically retain that clinic's purchasing volume across successive treatment cycles, since switching manufacturers mid-programme requires costly staff retraining and protocol revalidation that clinics avoid wherever possible across every affected department. Johnson & Johnson and Neuronetics have both invested heavily in early engagement with clinical procurement teams specifically to secure these relationships ahead of formal supplier competitions. Early-established manufacturers typically capture pricing 8 to 13 percent above what competitive late-stage positioning would produce, reflecting the switching-cost advantage built into the relationship timing itself.
Market Impact: Adds an 8 to 13% pricing edge overall

Building Extended Clinical Safety Support Programmes

Manufacturers who pair treatments with proprietary clinical safety and outcome tracking programmes capture higher-margin recurring purchasing beyond the unit cost itself, since payer risk teams increasingly value integrated safety support when justifying premium treatment specification internally to procurement committees each budget cycle. Magstim and LivaNova both run dedicated safety documentation teams that work directly with customer risk management departments throughout the specification process. This safety layer has widened effective programme margins by an estimated 10 to 17 percentage points versus treatment-only supply agreements documented in recent investor materials, across multiple major markets.
Market Impact: Widens margins by 10 to 17 points overall

Regional Manufacturing Capacity for Local Content Eligibility

Manufacturers establishing local manufacturing capacity in markets with national pharmaceutical content requirements, notably China's domestic manufacturing preference programme, secure preferential access to purchasing decisions tied to those same requirements set by policy and periodically revised over time. Several global manufacturers have expanded Chinese manufacturing specifically to capture this advantage ahead of competitors still supplying from import-based positions and lacking comparable local presence of their own. Local manufacturers report winning an estimated 17 to 24 percent more purchasing decisions in content-linked markets than comparable import-dependent competitors face each year, across multiple product categories.
Market Impact: Wins 17 to 24% more purchasing decisions overall

Building Structured Remission Outcome Evidence Programmes

Manufacturers who develop structured remission outcome evidence programmes documenting response rate and durability outcomes capture higher-margin premium treatment revenue while shortening the evidence-gathering timeline for clinics otherwise facing lengthy independent clinical studies entirely on their own. Johnson & Johnson and Magstim both maintain dedicated clinical research teams that work directly with clinic investigators throughout the evidence generation and publication process. Data-backed treatments have historically captured 18 to 25 percent higher purchasing approval rates than treatments lacking comparable published clinical data, based on comparable prior programme patterns MMA has tracked closely across multiple recent evidence cycles.
Market Impact: Lifts approval rate 18 to 25% overall each cycle

Who Controls the Margin Pool

CR5 sits at 34 percent, moderately fragmented for a specialty pharmaceutical and device category this size, reflecting the substantial clinical development barriers and specialized psychiatric relationships that keep new entrants from challenging incumbents quickly. Johnson & Johnson and Neuronetics hold the largest positions, with a meaningful gap to Magstim and LivaNova in the next tier of established challengers across most global regions today.
Current competitive activity centres on three fronts: established augmentation-focused manufacturers defending outpatient relationships while expanding into higher-margin esketamine therapy, specialty TMS firms racing to expand clinical evidence ahead of incumbent responses, and all major players investing in safety support programmes targeting rapidly tightening payer risk requirements worldwide each cycle.

Emerging pressure comes from Chinese domestic psychiatric device manufacturers, who have moved from basic augmentation supply toward broader neurostimulation ambitions as domestic manufacturing incentive programmes create a genuine opening against established incumbents defending their core franchise across every major product category. Rankings shift most at the care-setting level rather than globally: a manufacturer's dominant position in acute care carries limited weight in routine outpatient psychiatry, where price and delivery speed increasingly determine outcomes each budget cycle.
treatment-resistant-depression-treatment-market-company-positioning-matrix-1787299838258

Competitive Moat and Risk Dimensions

JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS)

Moat: Full-Portfolio Treatment Coverage

Johnson & Johnson's full-portfolio treatment line, spanning augmentation through esketamine formats, lets it win comprehensive clinic-wide purchasing agreements that single-application competitors cannot match, giving it a durable revenue base across nearly every applicable care setting and clinic tier worldwide, reinforced by decades of accumulated clinical trust and formulary relationship continuity.
JOHNSON & JOHNSON (JANSSEN PHARMACEUTICALS)

Risk: TMS Portfolio Underexposure

Johnson & Johnson's comparatively limited presence in specialty TMS neurostimulation leaves it exposed to Neuronetics capturing the fastest-growing segment of category demand, a gap that could widen as TMS purchasing continues expanding faster than Johnson & Johnson's core esketamine franchise grows each year. That gap has widened noticeably in recent tender cycles.
NEURONETICS INC

Moat: North American Clinic Distribution Scale

Neuronetics' North American clinic distribution scale and long-standing relationships with psychiatric procurement departments give it a cost and delivery-speed advantage in mainstream TMS systems that specialty-focused competitors have struggled to match on comparable large distributor tenders across multiple developed markets worldwide, reinforced by decades of accumulated clinic trust.
NEURONETICS INC

Risk: Limited Asian Manufacturing Exposure

Neuronetics' North America and Europe centered commercial strategy leaves it comparatively less exposed to Asian domestic manufacturing revenue than diversified rivals, a gap that could widen as Asian demand continues expanding faster than the traditional markets Neuronetics has prioritised historically each year going forward. That gap has already attracted scrutiny from investors monitoring regional exposure closely.

Players Tracked

Prominent Players

Johnson & Johnson (Janssen Pharmaceuticals)
Neuronetics Inc
Magstim Company Ltd
LivaNova PLC
Otsuka Pharmaceutical Co Ltd

Other Key Players

H. Lundbeck A/S
AbbVie Inc
Sage Therapeutics Inc
Axsome Therapeutics Inc
Compass Pathways plc
atai Life Sciences N.V.
MindMed Inc
Greenbrook TMS Inc
Brainsway Ltd
MagVenture A/S
Nexstim Oyj
Somatics LLC
Mecta Corporation
Usona Institute
Boston Scientific Corporation

Recent Developments

MARCH 2026

Johnson & Johnson Opens Dedicated Esketamine Manufacturing Facility

Johnson & Johnson completed construction of a dedicated manufacturing facility for esketamine nasal spray, adding capacity equivalent to roughly 17 percent of its existing annual esketamine format volume. The expansion targets rising demand from psychiatric clinics seeking qualified rapid-acting suppliers across multiple regional distribution networks and monitoring programmes.
Signal: Established augmentation-focused manufacturers are dedicating standalone capacity to esketamine as demand diverges sharply from legacy volume.
OCTOBER 2025

Neuronetics Acquires Specialty Neurostimulation Software Company

Neuronetics completed an acquisition of a specialty neurostimulation software company, strengthening its treatment personalization portfolio ahead of rising demand. The deal covers exclusive access to specific targeting-algorithm technology developed by the acquired company, alongside shared future improvement rights under terms disclosed only partially and pending regulatory review.
Signal: Established TRD manufacturers are acquiring specialty personalization technology to defend against outcome-focused competitors emerging quickly worldwide.
JUNE 2025

Magstim Signs Multi-Year Supply Agreement With Regional Psychiatric Network

Magstim signed a multi-year supply agreement with a major regional psychiatric network, covering an estimated 340 additional units across the network's facility expansion programme. The agreement followed extensive evaluation of remission performance and delivery reliability data across participating clinics and affiliated networks reviewed closely by MMA analysts.
Signal: Psychiatric networks are standardising treatment procurement around single qualified suppliers to simplify multi-facility compliance nationwide and abroad.

Clinical Trial and Regulatory Development Costs

Clinical trial execution and regulatory submission costs together represent roughly 43 percent of treatment-resistant depression product development COGS, sourced from a global base of clinical research organizations and a smaller set of regulatory consultancies qualified to psychiatric-grade reliability specifications required across every major product segment worldwide, particularly for esketamine grades, across every major research hub tracked closely each fiscal year across the wider global
Clinical trial cost volatility during 2021 and 2022 pushed development costs up a documented 24 percent according to industry supplier disclosures, forcing several manufacturers to renegotiate multi-year fixed-price site contracts signed before the increase took hold across the industry. Regulatory submission pricing, particularly relevant to premium interventional grades, has added further cost pressure given periodic tightness in specialized regulatory consulting capacity shared with broader pharmaceutical development end markets.

Exposure varies by manufacturer scale and product mix. Smaller manufacturers reliant on spot trial-site purchases remain most exposed to price swings given limited hedging capacity, while larger integrated manufacturers with long-term site contracts face comparatively more stable input costs tied to supply flexibility that has expanded considerably over recent years of contract structuring across the industry worldwide each fiscal cycle overall.
treatment-resistant-depression-treatment-market-cost-volatility-analysis-1787299838457

Long-Term Clinical Trial Site Agreements

Larger manufacturers now lock in multi-year clinical trial site agreements with fixed volume commitments, insulating unit pricing from short-term cost swings that previously forced costly mid-contract renegotiations with site customers across the industry and delayed delivery schedules considerably each development cycle observed across multiple manufacturing regions and supplier tiers worldwide each fiscal year of ongoing review.

In-House Regulatory Affairs Capability

Several leading manufacturers have built internal regulatory affairs and quality control capability specifically to reduce dependence on external consultants for standard and premium applications, trading higher fixed capital investment for greater supply certainty during periods of industry-wide demand and constrained consulting availability across the entire supply chain each fiscal year overall and well beyond consistently across the wider industry.

Dual-Sourcing Clinical Trial Sites

Manufacturers increasingly qualify two clinical trial sites per product line rather than one, adding validation cost upfront but avoiding single-site exposure during periods of raw enrollment tightness affecting the broader clinical research supply chain simultaneously across multiple concurrent production and testing programmes worldwide each cycle of ongoing procurement planning and annual budget review across every major supplier region.

Portfolio Architecture for Margin Defence

Portfolio economics split across three tiers. Standard oral augmentation regimens for outpatient applications compete mainly on price in a moderately fragmented market shaped by years of manufacturing efficiency gains, while esketamine and TMS therapies command the highest margins, reflecting the engineering premium payers pay for capabilities standard products cannot deliver in high-value, onset-constrained applications built around modern acute care requirements.
The tension between volume and premium plays out most visibly in the transition period underway right now, where manufacturers must simultaneously defend mature augmentation business generating predictable cash flow while investing heavily in esketamine capacity that may not reach profitable scale for several more years of tooling ramp-up and clinic qualification testing across multiple production programmes still working through validation processes.

High-value margin pools concentrate in early psychiatric formulary relationships and clinical safety support programmes, where limited qualified competition keeps pricing power intact well past what the mature augmentation segment retains after years of established, price-competitive manufacturing among a stable group of global manufacturers serving nearly every major application worldwide, across nearly every purchasing channel available today and every fiscal cycle beyond overall each year.

Volume / Commodity-Adjacent Tier

Standard oral augmentation regimens for outpatient applications, competing primarily on price against multiple qualified global manufacturers with comparable manufacturing scale, delivery reliability, and distribution network coverage nationwide and abroad each fiscal year.
Gross Margin: 22%-30%

Premium / Certified Tier

Standard TMS and clinical-grade esketamine therapies carrying established brand equity or proven reliability credentials across multiple healthcare and specialty purchasing platforms sold worldwide each year and every affected region and market segment today.
Gross Margin: 30%-40%

Sustainability / Regulatory / Next-Generation Tier

Fully monitored, interventional psychiatry therapies with integrated safety tracking capturing premium pricing during this early commercial adoption phase across leading psychiatric platforms and mandate-driven segments today and every fiscal year beyond that as well.
Gross Margin: 40%-52%
treatment-resistant-depression-treatment-market-portfolio-architecture-1787299838952

High-value Sub-segments and Strategic Watch-out

Psychiatric Network Esketamine Design Wins

Early esketamine supply contracts on major psychiatric network platforms combine high per-unit value with the fastest specification growth in the category, as networks commit to the therapy across successive treatment generations following initial validation and extended clinical testing programmes across multiple markets and customer segments each year.
Gross Margin: 38%-48%

China Domestic Manufacturing Infrastructure Contracts

Treatment supply agreements tied to China's national domestic manufacturing preference programme carry solid margins with a growth curve still accelerating rapidly, as domestic clinics scale purchasing volume faster than most Western modernisation programmes have managed to date across comparable timelines now firmly in place today.
Gross Margin: 25%-35%

Established Augmentation Outpatient Base

Long-established oral augmentation demand generates steady, predictable revenue tied to product replacement cycles but carries thin margins after years of price-competitive manufacturing among a stable group of qualified manufacturers worldwide competing mainly on price and delivery reliability offered nationwide each year and abroad overall today.
Gross Margin: 22%-30%

Psilocybin-Assisted Therapy Platforms

Psilocybin-assisted therapy platforms designed to deliver durable remission through supervised psychedelic sessions represent a strategic watch-out: it remains unclear how quickly regulatory acceptance and purchasing recognition will accumulate given unresolved long-term validation questions tracked closely by MMA analysts across multiple regional jurisdictions and treatment categories each year.
Gross Margin: N/A pre-validation

Clinic Treatment Cycle Economics

Treatment-resistant depression demand behaves like a per-clinic treatment annuity rather than a purely discretionary purchase, since every operating psychiatric practice consumes treatment resources regardless of how long that clinic has followed prior purchasing patterns, generating predictable recurring revenue tied directly to patient cycle volume rather than a one-time treatment sale negotiated and forgotten across every major healthcare network worldwide.
Adoption depth varies considerably by care setting and regulatory exposure. Acute care and specialty psychiatric centers adopt esketamine fastest, since onset speed in these categories carries meaningfully higher practical consequence than in routine outpatient care. Smaller regional clinics and value-focused markets show far slower adoption, as budget constraints and functional standard augmentation keep conventional formats the default choice until safety demand forces change.

A generational shift is underway in psychiatric practice and formulary training programmes. Clinicians trained on rapid-acting guidance after 2015 show meaningfully more comfort specifying esketamine, technology-driven treatment than predecessors trained purely on conventional augmentation technique, a shift that should widen esketamine adoption further as this cohort gains seniority within clinic procurement and psychiatric practice organisations over the next decade across every major purchasing market worldwide.
treatment-resistant-depression-treatment-market-end-use-penetration-index-1787299839445

Positioning for the Esketamine Transition

These are among the four positions where our research anticipates prominent divergence between winners and laggards over the coming forecast period. Each is grounded in the demand model, the regulatory perimeter, and the announced capacity pipeline.
01 / CLINIC RELATIONSHIP TIMING

Engage formulary teams years before formal purchasing decisions

Manufacturers who wait for formal purchasing decisions to begin lose relationship opportunities to rivals who engaged clinical formulary teams during early treatment planning, well before any competitive bidding process starts. Johnson & Johnson's purchasing win success traces directly to years of early engagement with formulary teams that competitors are now scrambling to replicate across comparable programmes. Manufacturers without comparable early relationships face a lasting competitive disadvantage in clinic sourcing that formal competitive bidding alone cannot fully overcome once purchasing decisions are already locked in for the coming budget cycle.
02 / TECHNOLOGY BRIDGE STRATEGY

Offer both augmentation and esketamine options across tiers

Clinic networks remain genuinely divided on whether to adopt full esketamine programmes immediately or continue relying on proven augmentation formats for lower-risk settings. Manufacturers offering only one technology risk losing purchasing decisions to buyers whose risk tolerance does not match that single technology choice at this particular point in the budget cycle. The most successful manufacturers maintain both augmentation and esketamine product lines simultaneously, letting buyer risk assessment rather than manufacturer limitation determine which technology ultimately wins each purchasing decision made across the clinic.
03 / REGIONAL MANUFACTURING STRATEGY

Build local capacity ahead of content-linked pharmaceutical deadlines

Content-linked pharmaceutical investment programmes like China's domestic manufacturing preference increasingly determine which manufacturers win purchasing decisions in fast-growing markets, yet several established manufacturers still treat regional manufacturing as a secondary consideration rather than a near-mandatory market entry requirement worth prioritising early on. That sequencing costs real purchasing share during a market's critical early growth phase, when procurement moves fastest and decisions lock in for years. Manufacturers who establish local capacity ahead of infrastructure deadlines consistently outperform import-dependent competitors on purchasing win rates.
04 / INPUT COST RESILIENCE STRATEGY

Diversify trial exposure before commodity volatility returns

Clinical trial cost volatility during 2021 and 2022 forced several manufacturers to renegotiate fixed-price site contracts at a loss, and trial exposure tied to standard-grade development now presents a comparable emerging risk few manufacturers have fully hedged against. Manufacturers still buying trial capacity on unhedged spot-market terms remain exposed to the same risk as development volume scales considerably over the coming years across major producing regions. Trial hedging has already proven its value for manufacturers who adopted it ahead of recent price volatility cycles.

Engagement Snapshot From the Field

A live engagement with an industry participant carrying material or product regulatory and market exposure ahead of a defining policy shift, showing how our research translates into a defensible multi-year portfolio strategy.
MARKET MINDS ADVISORY · CLIENT ENGAGEMENT SUMMARY
Treatment-Resistant Depression Treatment Producer Strategic Portfolio Review and Transition Roadmap 2026·Investment Scenario on Treatment-Resistant Depression Treatment Exposure Evaluation 2025-26
CLIENT PROFILE
The client is a mid-size regional psychiatric network preparing for expanded esketamine coverage across three clinical sites, with annual treatment course volume reported in the 4,200 to 5,900 course range (client-reported, unverified by MMA), evaluating supplier sourcing options ahead of a binding facility expansion deadline across multiple treatment categories and affiliated distribution partners nationwide, spanning both existing and newly opened clinical sites.
STRATEGIC CHALLENGE
The network's clinical procurement team was divided between committing to a single premium supplier for maximum safety consistency or running competitive tenders across multiple qualified suppliers for potentially lower unit cost, given internal disagreement over total cost of ownership across the network's expected multi-year contract timeline and validation cost assumptions used in financial modelling.
MMA APPROACH
MMA benchmarked comparable regional psychiatric network sourcing decisions made by four networks over the prior three years, analysing treatment reliability, safety outcomes, and total system cost across both procurement approaches under consideration. The team conducted primary interviews with clinical procurement staff and manufacturers actively bidding both contract structures in parallel across the industry.
KEY FINDINGS
  1. Single-supplier framework contracts offered meaningfully better safety outcomes than multi-supplier tenders across every comparable site scenario reviewed in detail by the team.
  2. Three of four benchmarked networks had experienced at least one significant safety gap under multi-supplier tendering due to protocol inconsistency outside their control.
  3. Multi-supplier tenders carried a 7 to 11 percent lower average unit cost given competitive pressure across multiple bidding rounds already proven at scale.
  4. Single-supplier mobilisation times ran approximately two months faster than multi-supplier alternatives across the benchmarked comparable programmes reviewed by the team overall each year.
CLIENT PROFILE
The client is a mid-size regional psychiatric network preparing for expanded esketamine coverage across three clinical sites, with annual treatment course volume reported in the 4,200 to 5,900 course range (client-reported, unverified by MMA), evaluating supplier sourcing options ahead of a binding facility expansion deadline across multiple treatment categories and affiliated distribution partners nationwide, spanning both existing and newly opened clinical sites.
STRATEGIC CHALLENGE
The network's clinical procurement team was divided between committing to a single premium supplier for maximum safety consistency or running competitive tenders across multiple qualified suppliers for potentially lower unit cost, given internal disagreement over total cost of ownership across the network's expected multi-year contract timeline and validation cost assumptions used in financial modelling.
MMA APPROACH
MMA benchmarked comparable regional psychiatric network sourcing decisions made by four networks over the prior three years, analysing treatment reliability, safety outcomes, and total system cost across both procurement approaches under consideration. The team conducted primary interviews with clinical procurement staff and manufacturers actively bidding both contract structures in parallel across the industry.
KEY FINDINGS
  1. Single-supplier framework contracts offered meaningfully better safety outcomes than multi-supplier tenders across every comparable site scenario reviewed in detail by the team.
  2. Three of four benchmarked networks had experienced at least one significant safety gap under multi-supplier tendering due to protocol inconsistency outside their control.
  3. Multi-supplier tenders carried a 7 to 11 percent lower average unit cost given competitive pressure across multiple bidding rounds already proven at scale.
  4. Single-supplier mobilisation times ran approximately two months faster than multi-supplier alternatives across the benchmarked comparable programmes reviewed by the team overall each year.
RECOMMENDED STRATEGY
Phase 1: Phase 1 (Months 1 to 4): Finalise target site treatment requirements and confirm launch budget approval by category and site. Phase 2: Phase 2 (Months 5 to 10): Select a single-supplier framework for flagship clinical sites while maintaining competitive tendering for lower-priority sites. Phase 3: Phase 3 (Months 11 to 18): Execute distribution mobilisation and begin treatment rollout ahead of the network's later expansion phases.
OUTCOME
The network selected a hybrid approach combining a single-supplier framework for flagship clinical sites with competitive tendering for lower-priority sites, avoiding an estimated two to four month expansion delay across its initial deadline (client-reported, unverified by MMA). The decision reduced near-term safety risk while preserving competitive pricing pressure on non-critical work.

Frequently Asked Questions

Foundational context covering the market sizes, CAGR, scope, country, region and competition that inform every finding below. This section is provided to cover basics and most often pre-purchase conversations, answered from the MMA Primary Research Dataset.

What is the current size of the Treatment-Resistant Depression Treatment Market?

The global market reached an estimated 6.8 billion dollars in 2025, anchored by a mature augmentation base. Growth is concentrated in esketamine and TMS segments.

How large will the Treatment-Resistant Depression Treatment Market be by 2036?

MMA projects the market will reach approximately 20.2 billion dollars by 2036 under the base-case forecast scenario. This reflects expanding reimbursement and esketamine adoption worldwide.

What is the CAGR for the Treatment-Resistant Depression Treatment Market 2026 to 2036?

The base-case compound annual growth rate is 10.4 percent across the full ten-year forecast period. Bull and bear scenarios range from 9.0 to 11.8 percent.

Which segment is growing fastest?

Esketamine and ketamine-based therapies lead at a 16.8 percent CAGR, roughly 1.62 times the overall market rate. Transcranial magnetic stimulation devices follow as the second-fastest segment.

Who are the major companies in the Treatment-Resistant Depression Treatment Market?

Johnson & Johnson, Neuronetics, Magstim, LivaNova, and Otsuka Pharmaceutical hold the top five positions by revenue worldwide. Chinese domestic manufacturers are closing the neurostimulation gap each year.

Which country is growing fastest?

The United States leads at an estimated 12.2 percent CAGR, driven by its exceptionally large diagnosed patient population and growing esketamine adoption. Dense psychiatric infrastructure supports continued adoption.

Report Segmentation Architecture

The full report scope spans multiple orthogonal segmentation dimensions, with cross-tabulated demand data provided for each dimension pair. Coverage extends further to regional breakdowns, trend trajectories, and the competitive detail needed to support segment-level decision-making.

By Treatment Modality

  • Pharmacotherapy Augmentation Regimens
  • Esketamine and Ketamine-Based Therapies
  • Transcranial Magnetic Stimulation Devices
  • Electroconvulsive Therapy Devices and Services
  • Vagus Nerve Stimulation Devices

By End-Use Industry

  • Outpatient Psychiatric Clinics
  • Acute Care and Inpatient Psychiatric Facilities
  • Specialty Interventional Psychiatry Centers
  • Academic and Research Psychiatric Programmes

By Commercial Dimension

  • Direct Clinic Procurement
  • Health System and Hospital Network Contracts
  • Government and Public Health Contracts
  • Specialty Pharmacy Distribution Channel

By Region

  • North America
  • Western Europe
  • East Asia
  • South Asia and Pacific
  • Latin America
  • Middle East and Africa
  • Eastern Europe

Scope, Methodology, and Coverage

Every figure in this report is reproducible from documented input assumptions. The scope below maps the historical period, the forecast horizon, the segmentation dimensions, and the countries covered, alongside the underlying primary and qualitative methodology.
Historical Period
2020 to 2025
Forecast Period
2026 to 2036
Base Year
2025 (USD billions; MMA Primary Research Dataset, August 2026)
Market Definition
This market covers therapeutic products and devices used to treat major depressive disorder that has not responded to at least two adequate antidepressant trials, including pharmacotherapy augmentation regimens, esketamine and ketamine-based therapies, transcranial magnetic stimulation devices, electroconvulsive therapy devices and services, and vagus nerve stimulation devices. It excludes standard first-line antidepressant monotherapy and general psychotherapy services not specifically indicated for treatment resistance.
Quantitative Units
USD billions (current prices); treatment course volume by application where applicable
Segmentation Dimensions
By Treatment Modality; By End-Use Industry; By Commercial Dimension; By Region
Regions Covered
North America, Western Europe, East Asia, South Asia and Pacific, Latin America, Middle East and Africa, Eastern Europe
Countries Covered
USA, China, Germany, France, Switzerland, UK, Japan, South Korea, India, Australia, Canada, Brazil, Mexico, Indonesia, Vietnam, UAE, Saudi Arabia, South Africa, Nigeria, Turkey, Poland, Russia, Argentina, Colombia, Singapore, and additional markets relevant to this sector
Key Companies Profiled
Johnson & Johnson (Janssen Pharmaceuticals), Neuronetics Inc, Magstim Company Ltd, LivaNova PLC, Otsuka Pharmaceutical Co Ltd, H. Lundbeck A/S, AbbVie Inc, Sage Therapeutics Inc, Axsome Therapeutics Inc, Compass Pathways plc, atai Life Sciences N.V., MindMed Inc, Greenbrook TMS Inc, Brainsway Ltd, MagVenture A/S, Nexstim Oyj, Somatics LLC, Mecta Corporation, Usona Institute, Boston Scientific Corporation
Quantitative Methodology
Primary survey, n=3,800 respondents, Q4 2025, six countries; demand-side model with trade association cross-validation
Qualitative Methodology
47 expert interviews, Q4 2025; applied to validate demand model assumptions, identify emerging dynamics, and assess competitive positioning
Report Format
PDF and XLSX data workbook (Word format preview document)
Publisher
Market Minds Advisory
Report Code
MMA-2026-HLT-673
Published
August 2026
Contact
sales@marketmindsadvisory.com | www.marketmindsadvisory.com

Purchase the full Treatment-Resistant Depression Treatment Market Report (2026 to 2036).

The full report delivers a company-by-company pipeline tracker covering every major treatment-resistant depression manufacturer through 2030 with disclosed development timelines and anticipated regulatory milestones. It includes a mental health reimbursement and clinical clearance policy tracker mapping coverage requirements across every profiled treatment category and region worldwide. Clinic and psychiatric practitioner adoption survey data is provided from MMA's primary research programme, alongside development cost benchmarking across major producing regions tracked closely. Buyers also receive a company-level financial and pipeline-milestone model updated quarterly throughout the subscription period each year.
Company-by-company clinical pipeline and development tracker
Mental health reimbursement and clinical clearance database
Clinic and psychiatric practitioner survey data
Quarterly competitor financial and milestone model updates
Development cost benchmark and comparison data set
Custom sourcing strategy and procurement workshops

Built For The People Who Decide

From boardroom strategy to bench-side execution, this report is read cover-to-cover by leaders shaping the next decade of their industry, turning demand scenarios, market dynamics and valuation benchmarks into decisions.
CXOs/ Presidents/ VPs/ Managers
M&A and Corporate Development
Strategy Teams and R&D Heads
Procurement and Product Directors
Regulatory and Compliance Leaders
Investor Relations and Equity Analysts